All In Biotech

Drug Trial Radar · NCT06561386

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy as First-line Treatment for Participants With Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and With Tumor Cell PD-L1 Expression ≥ 1%

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,000 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,000

Planned (sponsor's estimate)

Start

Oct 7, 2024

Primary completion

Jul 30, 2030

Study completion Aug 4, 2032

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Aug 20, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD-L1 expression ≥ 1%

Conditions

  • Non-small Cell Lung Cancer

Interventions

  • NivolumabDrug

    Specified dose on specified days

  • RelatlimabDrug

    Specified dose on specified days

  • PembrolizumabDrug

    Specified dose on specified days

  • CarboplatinDrug

    Specified dose on specified days

  • PemetrexedDrug

    Specified dose on specified days

  • CisplatinDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survival (OS) in randomized participants with PD-L1 1% to 49%Time frame: Up to 5 years

Locations

330 sites in 31 countries. Site status is shown where the registry gives one.

  • Local Institution - 0487

    Mobile, Alabama · Not yet recruiting

  • Southern Arizona VA Health Care System

    Tucson, Arizona · Recruiting

  • Local Institution - 0112

    Los Angeles, California · Withdrawn

  • University of California Davis (UC Davis) Comprehensive Cancer Center

    Sacramento, California · Recruiting

  • Local Institution - 0159

    San Francisco, California · Completed

  • UCLA Hematology/Oncology - Santa Monica

    Santa Monica, California · Recruiting

  • Local Institution - 0500

    Grand Junction, Colorado · Not yet recruiting

  • Local Institution - 0472

    Westminster, Colorado · Not yet recruiting

  • Local Institution - 0206

    Miami, Florida · Completed

  • Local Institution - 0162

    Pembroke Pines, Florida · Completed

  • Florida Cancer Specialists - North

    St. Petersburg, Florida · Recruiting

  • Florida Clinical Trials Group.

    Tamarac, Florida · Recruiting

  • Florida Cancer Specialists - East

    West Palm Beach, Florida · Recruiting

  • Local Institution - 0509

    Coeur d'Alene, Idaho · Not yet recruiting

  • Local Institution - 0376

    Chicago Ridge, Illinois · Completed

  • Cancer Center of Kansas

    Wichita, Kansas · Recruiting

  • Saint Elizabeth Medical Center Edgewood

    Edgewood, Kentucky · Recruiting

  • Baptist Health Lexington

    Lexington, Kentucky · Recruiting

  • Local Institution - 0502

    Paducah, Kentucky · Not yet recruiting

  • Velocity Clinical Research, Annapolis

    Annapolis, Maryland · Recruiting

  • Profound Research LLC - MHP MedOnc Royal Oak - Oakland Medical Group Location

    Royal Oak, Michigan · Recruiting

  • Local Institution - 0226

    Hattiesburg, Mississippi · Completed

  • Local Institution - 0498

    Kansas City, Missouri · Not yet recruiting

  • Local Institution - 0308

    Bozeman, Montana · Completed

  • Renown Regional Medical Center

    Reno, Nevada · Recruiting

  • Local Institution - 0507

    Morristown, New Jersey · Not yet recruiting

  • Local Institution - 0346

    Paterson, New Jersey · Completed

  • Local Institution - 0523

    Summit, New Jersey · Not yet recruiting

  • Local Institution - 0381

    Albuquerque, New Mexico · Completed

  • Local Institution - 0356

    Hawthorne, New York · Completed

  • Veterans Affairs New York Harbor Healthcare System

    New York, New York · Recruiting

  • Local Institution - 0380

    Northport, New York · Withdrawn

  • University of Rochester Medical Center

    Rochester, New York · Recruiting

  • Local Institution - 0511

    Schenectady, New York · Not yet recruiting

  • SUNY Upstate Medical University

    Syracuse, New York · Recruiting

  • Local Institution - 0357

    The Bronx, New York · Withdrawn

  • Local Institution - 0352

    Asheville, North Carolina · Completed

  • East Carolina University

    Greenville, North Carolina · Recruiting

  • Local Institution - 0369

    Canton, Ohio · Withdrawn

  • Local Institution - 0486

    Centerville, Ohio · Not yet recruiting

Showing 40 of 330 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.